Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by B. Christian
A Phase Ii Trial of Brentuximab Vedotin (Bv) and Lenalidomide (Len) in Relapsed and Refractory (R/R) Cutaneous (Ctcl) and Peripheral (Ptcl) T-Cell Lymphomas: Preliminary Results of a Phase Ii Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase I Dose-Escalation Study of Venetoclax Plus Beam Followed by Autologous Stem Cell Transplant (Asct) for Chemoresistant, Relapsed/Refractory, or High-Risk Non-Hodgkin's Lymphoma (Nhl); Preliminary Results
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Polatuzumab Vedotin (Pola) + Obinutuzumab (G) + Lenalidomide (Len) in Patients (Pts) With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Phase Ib/Ii Interim Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas
American Journal of Hematology
Hematology
Laboratory Correlates for a Phase II Trial of Romidepsin in Cutaneous and Peripheral T-Cell Lymphoma
British Journal of Haematology
Hematology
Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
Response to Brentuximab Vedotin by Cd30 Expression: Results From Five Trials in Ptcl, Ctcl, and B-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
